<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The implication of DNA hypermethylation in the pathogenesis of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) provides a rationale for using hypomethylating agents such as <z:chebi fb="0" ids="2038">azacitidine</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Growing evidence suggests that <z:chebi fb="0" ids="2038">azacitidine</z:chebi> may reverse epigenetic gene silencing at specific genomic targets </plain></SENT>
<SENT sid="2" pm="."><plain>AZA-001 established <z:chebi fb="0" ids="2038">azacitidine</z:chebi> as the first agent to provide a significant overall survival benefit in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients </plain></SENT>
<SENT sid="3" pm="."><plain>These data confirmed that <z:chebi fb="0" ids="2038">azacitidine</z:chebi> has a progressively cumulative effect on the <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone and support the value of maintenance therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Prolonged survival was independent of achieving complete response </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="2038">Azacitidine</z:chebi> in combination with <z:chebi fb="0" ids="15358">histone</z:chebi> deacetylase inhibitors might offer better efficacy by modulating the methylation and acetylation states of silenced genes </plain></SENT>
</text></document>